Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavilermide for Dry Eye Disease
NCT05848128Phase 3Completed
- Sponsor
- Mimetogen Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tavilermide in dry eye disease (DED), sponsored by Mimetogen Pharmaceuticals. Started Jun 2023; status: completed.
02
Drugs
tavilermide
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05848128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848128.